EMAIL THIS PAGE TO A FRIEND

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.


PMID 26111977

Abstract

Intraductal tubulopapillary neoplasm is a well-established entity in the pancreas. A similar, if not identical, tumor occurs also in the biliary tract. We conducted a multicenter study of 20 such lesions, focusing on their clinicopathologic characteristics and molecular profile. Biliary intraductal tubulopapillary neoplasms were seen in patients in their 60s (mean 62 years). The tumors were intrahepatic 70%, extrahepatic 10%, and perihilar 20%; mean tumor size was 6.9 cm. Histologically, all intraductal tubulopapillary neoplasms showed, in addition to their typical tubular pattern, solid areas (70%) or abortive papillae (50%). Necrosis was common (85%), predominantly focal (40%), and with 'comedocarcinoma-like pattern' in 40%. Immunohistochemically, these neoplasms were characterized by the expression of MUC1 (80%) and MUC6 (30%) and by the absence of MUC2 and MUC5AC. Associated invasive carcinomas were present in 16 (80%), mainly conventional tubular adenocarcinoma (50%). The molecular alterations observed included CDKN2A/p16 (intraductal components 44%, invasive 33%) and TP53 (intraductal components 17%, invasive 9%). Mutations in KRAS (intraductal 6%, invasive 0%), PIK3CA (intraductal 6%, invasive 0%), and loss of SMAD4/DPC4 (intraductal 7%, invasive 0%) were rare. No alterations/mutations were identified in IDH1/2, BRAF, GNAS, EGFR, HER2, and β-catenin. Follow-up information was available for 17 patients (85%) with mean follow-up 44 months. Overall combined survival rates showed favorable prognosis: 1 year 100%, 3 years 90%, and 5 years 90%. In conclusion, despite the relatively high incidence of invasive carcinoma (80%), available follow-up suggests that biliary intraductal tubulopapillary neoplasms have an indolent behavior. Molecular analyses highlight the low prevalence of alterations of common oncogenic signaling pathways in intraductal tubulopapillary neoplasm. Further studies using whole-exome sequencing are required to discover yet unknown molecular changes and to understand the carcinogenesis of intraductal tubulopapillary neoplasms.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW21185 Anti-CDKN2A antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB2502016
Anti-Cdkn2a antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501929
Anti-CDKN2A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB4500784
Anti-HER2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4500785
Anti-HER2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4500786
Anti-HER2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4500788
Anti-HER2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB1412430 ANTI-MUC2 antibody produced in mouse, clone 4A4, purified immunoglobulin, buffered aqueous solution
SAB1412431 ANTI-MUC2 antibody produced in mouse, clone 3D10, purified immunoglobulin, buffered aqueous solution
SAB1412432 ANTI-MUC2 antibody produced in mouse, clone 3A9, purified immunoglobulin, buffered aqueous solution
SAB1412433 ANTI-MUC2 antibody produced in mouse, clone 1H2, purified immunoglobulin, buffered aqueous solution
SAB1412448 ANTI-MUC2 antibody produced in mouse, clone 3D6, purified immunoglobulin, buffered aqueous solution
SAB1412598 ANTI-MUC2 antibody produced in mouse, clone 2A9, purified immunoglobulin, buffered aqueous solution
HPA040615
Anti-MUC5AC antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1306566
ANTI-P16INK4A (C-TERM E119) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1412048
ANTI-SMAD4 antibody produced in mouse, clone 4C5, purified immunoglobulin, buffered aqueous solution
SAB1412049
ANTI-SMAD4 antibody produced in mouse, clone 4C6, purified immunoglobulin, buffered aqueous solution
SAB1412182
ANTI-SMAD4 antibody produced in mouse, clone 3D7, purified immunoglobulin, buffered aqueous solution
SAB1412494
ANTI-SMAD4 antibody produced in mouse, clone 4A6, purified immunoglobulin, buffered aqueous solution
SAB1412495
ANTI-SMAD4 antibody produced in mouse, clone 2G4, purified immunoglobulin, buffered aqueous solution
SAB1412496
ANTI-SMAD4 antibody produced in mouse, clone 3H1, purified immunoglobulin, buffered aqueous solution
SAB1412497
ANTI-SMAD4 antibody produced in mouse, clone 2C1, purified immunoglobulin, buffered aqueous solution
SAB1412498
ANTI-SMAD4 antibody produced in mouse, clone 4D12, purified immunoglobulin, buffered aqueous solution
SAB1412512
ANTI-SMAD4 antibody produced in mouse, clone 1A5, purified immunoglobulin, buffered aqueous solution
SAB1412596
ANTI-SMAD4 antibody produced in mouse, clone 1G9, purified immunoglobulin, buffered aqueous solution
SAB1412597
ANTI-SMAD4 antibody produced in mouse, clone 2E7, purified immunoglobulin, buffered aqueous solution
HPA019154
Anti-SMAD4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4200405
Anti-SMAD4 antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB2106277
Anti-SMAD4 antibody produced in rabbit, affinity isolated antibody
WH0004583M2
Monoclonal Anti-MUC2 antibody produced in mouse, clone 1D10, purified immunoglobulin, buffered aqueous solution